found that the COX-2 inhibitor celecoxib decreased the development of new BCCs in patients with PTCH1 +/− basal cell nevus syndrome, but it did not reach statistical significance [ 44 ].
1
—
—
found that the COX-2 inhibitor celecoxib decreased the development of new BCCs in patients with PTCH1 +/− basal cell nevus syndrome, but it did not reach statistical significance [ 44 ].